ReviewJournal of molecular neuroscience : MN2005
No go for brain tumors?
Review in Journal of molecular neuroscience : MN, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor.Neuroscience bulletin · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Nogo gene and its products are well known as adult central nervous system (CNS) myelin inhibitors of neuronal regeneration. We review here experimental findings that might link Nogo to CNS malignancy. These links are founded on two very different modes of cellular action by Nogo isoforms. Acting intracellularly and in conjunction with other molecules, cytoplasmic domains of Nogo might predispose cancer cells to apoptotic susceptibility. On the other hand, extracellular domains of Nogo might inhibit the migration and invasion of CNS tumors. Depending on the physiological context, Nogo isoforms might therefore be antitumorigenic or have tumor-suppressing activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.